Newsletter April 2022

We propose a condensate of ImaBiotech Group’s updates, activities and publications on a quarterly manner. We are proud to be an active global bioanalytical CRO, providing a unique set of services spanning the drug development cycle, from early-stage discovery through Phase IV.

In this first quarterly release of 2022, we are happy to share ImaBiotech’s launch of an innovative Bioanalysis Service including drug distribution to quantify drug and metabolites in plasma and tissues. Also, ImaBiotech introduced a novel panel to its Imaging Mass Cytometry services to advance biomarker discovery and therapeutic development in March 2022.

This year, ImaBiotech exhibited at the AACR Conference in New Orleans and presented 2 posters. In May 2022, ImaBiotech will be exhibiting at the Society for Investigative Dermatology (SID) Annual Meeting in Portland, Oregon and in June, a oral presentation will be given at the ASMS Conference.

During the first quarter, ImaBiotech released a publication on Topical Bimiralisib showing meaningful cutaneous drug levels in healthy volunteers and mycosis fungoides patients but no clinical activity in a first-in-human, randomized controlled trial. Aslo, an application note on “Cell deconvolution to estimate cell type abundance from Spatial Transcriptomic data within Heterogeneous tissues” was published.

In February, as part of Imabiotech’s webinar series, Corinne Ramos, Director of R&D, hosted a webinar where she discussed the use of Fluidigm’s Hyperion platform (Imaging Mass Cytometry Services) and GeoMx® NanoString platform for biomarkers discovery and predicting response to a given treatment in a GLP-like environment.

You will also discover ImaBiotech’s services on High multiplexed immunohisto-staining (mIHC). You will be able to access all the white papers, publication and application note on our website’s dedicated Resources section.

Follow us on or www.linkedin/imabiotech

Discover our Videos on Youtube/ImaBiotech

Search news